XTAI3164
Market cap51mUSD
Dec 23, Last price
19.60TWD
1D
0.51%
1Q
-14.41%
Jan 2017
-16.60%
Name
GenMont Biotech Inc
Chart & Performance
Profile
GenMont Biotech Incorporation engages in the research, development, production, and sale of functional probiotic products in Taiwan. The company also offers probiotics with special functions; and original formula design and manufacturing, and equipment manufacturing services on health care food, as well as cooperates in the research, production, and clinical trial of various products. GenMont Biotech Incorporation was founded in 2000 and is headquartered in Tainan City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 318,015 -13.71% | 368,546 -13.88% | 427,929 31.59% | |||||||
Cost of revenue | 310,290 | 308,364 | 299,592 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 7,725 | 60,182 | 128,337 | |||||||
NOPBT Margin | 2.43% | 16.33% | 29.99% | |||||||
Operating Taxes | 5,732 | 18,797 | 29,823 | |||||||
Tax Rate | 74.20% | 31.23% | 23.24% | |||||||
NOPAT | 1,993 | 41,385 | 98,514 | |||||||
Net income | 32,991 -42.10% | 56,978 -49.64% | 113,132 85.82% | |||||||
Dividends | (60,460) | (95,008) | (49,215) | |||||||
Dividend yield | 2.83% | 4.63% | 2.33% | |||||||
Proceeds from repurchase of equity | 2,814 | 669 | ||||||||
BB yield | -0.13% | -0.03% | ||||||||
Debt | ||||||||||
Debt current | 4,598 | 1,060 | 2,112 | |||||||
Long-term debt | 89,669 | 68,030 | 63,354 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 2,368 | 2,368 | 2,318 | |||||||
Net debt | (306,260) | (91,117) | (139,167) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 34,599 | 137,948 | 111,658 | |||||||
CAPEX | (33,308) | (70,933) | (117,116) | |||||||
Cash from investing activities | (75,374) | (83,704) | (153,071) | |||||||
Cash from financing activities | (36,817) | (91,085) | (61,367) | |||||||
FCF | 40,759 | 9,647 | (22,397) | |||||||
Balance | ||||||||||
Cash | 328,302 | 400,943 | 421,729 | |||||||
Long term investments | 72,225 | (240,736) | (217,096) | |||||||
Excess cash | 384,626 | 141,780 | 183,237 | |||||||
Stockholders' equity | 1,072,020 | 1,136,347 | 1,163,514 | |||||||
Invested Capital | 1,125,171 | 1,363,915 | 1,342,378 | |||||||
ROIC | 0.16% | 3.06% | 7.69% | |||||||
ROCE | 0.51% | 3.99% | 8.40% | |||||||
EV | ||||||||||
Common stock shares outstanding | 86,570 | 86,660 | 86,741 | |||||||
Price | 24.70 4.22% | 23.70 -2.67% | 24.35 9.19% | |||||||
Market cap | 2,138,279 4.11% | 2,053,842 -2.76% | 2,112,143 7.56% | |||||||
EV | 1,964,834 | 2,108,618 | 2,120,921 | |||||||
EBITDA | 72,505 | 110,597 | 149,471 | |||||||
EV/EBITDA | 27.10 | 19.07 | 14.19 | |||||||
Interest | 973 | 755 | 766 | |||||||
Interest/NOPBT | 12.60% | 1.25% | 0.60% |